This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Platelet-derived growth factor receptor | |
|---|---|
| Name | Platelet-derived growth factor receptor |
| Organism | Human |
Platelet-derived growth factor receptor is a family of receptor tyrosine kinases that mediate responses to platelet-derived growth factors and influence cell proliferation, migration, and survival. First characterized in studies of serum growth factors, these receptors have been central to research in cell signaling, cancer biology, and tissue repair. Investigations spanning laboratories at institutions like Harvard University, Massachusetts Institute of Technology, Max Planck Society, Johns Hopkins University, and University of Cambridge have elucidated receptor structure, ligands, and downstream pathways.
The receptors are single-pass transmembrane proteins with an extracellular ligand-binding domain, a transmembrane helix, and an intracellular tyrosine kinase domain. Structural studies from groups at European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and Stanford University used crystallography and cryo-EM to resolve extracellular immunoglobulin-like domains and the juxtamembrane region. Two principal genes encode distinct protomers, giving rise to multiple isoforms through alternative splicing and proteolytic processing; these genetic mappings were refined by consortia such as the Human Genome Project and projects at the Wellcome Trust Sanger Institute. Isoform diversity affects ligand specificity, dimerization preferences, and downstream signaling, with splice variants characterized in cohorts from Mayo Clinic, Cleveland Clinic, and academic centers collaborating on transcriptome profiling.
Ligand binding induces dimerization and trans-autophosphorylation, creating docking sites for SH2-domain-containing adaptors and enzymes. Key downstream cascades engage effectors characterized in landmark studies at University of California, Berkeley, University of Oxford, and Yale University, including the RAS–RAF–MEK–ERK axis, the PI3K–AKT pathway, and PLCγ-mediated calcium signaling. Adaptor proteins and substrates identified in biochemical screens from Rockefeller University and Columbia University include GRB2, SOS1, SHP2, and STAT family members implicated in transcriptional programs described by labs at University of Chicago and University of Pennsylvania. Cross-talk with other receptor systems studied at Massachusetts General Hospital and Karolinska Institutet integrates signals from integrins, G protein–coupled receptors, and transforming growth factor–beta receptors in cellular contexts relevant to wound healing and angiogenesis.
Receptor activity is modulated by mechanisms uncovered in research at National Institutes of Health, Institut Pasteur, and Fred Hutchinson Cancer Center, including ligand availability, endocytic uptake, ubiquitination, and lysosomal degradation. Endocytosis via clathrin-dependent and -independent routes was characterized in work from laboratories at University College London and University of California, San Diego, revealing roles for E3 ligases such as CBL and sorting complexes characterized by teams at Princeton University. Post-translational modifications including phosphorylation, ubiquitinylation, and glycosylation influence recycling versus degradation decisions; perturbations of these processes have been modeled in studies at Salk Institute and University of Toronto to understand spatial-temporal signaling.
During embryogenesis and tissue homeostasis, these receptors regulate mesenchymal cell proliferation, migration, and differentiation, findings established in experiments from Harvard Medical School, University of California, San Francisco, and Ludwig Maximilian University of Munich. They are critical for development of vascular smooth muscle, pericytes, and fibroblast lineages, with in vivo genetic models deployed at Cold Spring Harbor Laboratory and Utrecht University demonstrating roles in organogenesis, angiogenesis, and repair after injury. Physiological processes modulated by receptor signaling include skeletal development, hematopoiesis, and stromal support in tissues examined by research groups at University of Michigan, Karolinska Institutet, and University of Edinburgh.
Aberrant activation via gene fusions, amplification, point mutations, or autocrine ligand loops contributes to oncogenesis and fibrotic disorders; seminal clinical correlations emerged from collaborations between Memorial Sloan Kettering Cancer Center, Mayo Clinic, and MD Anderson Cancer Center. Oncogenic rearrangements were identified in tumors such as gliomas, dermatofibrosarcoma protuberans, and certain leukemias in studies reported by teams at Stanford University School of Medicine and University of Texas MD Anderson Cancer Center. Dysregulated signaling also underlies pulmonary fibrosis, scleroderma, and proliferative vitreoretinopathy with clinical cohorts evaluated at Mount Sinai Hospital and University of Pittsburgh Medical Center. Biomarker development and genomic characterization leveraging resources from The Cancer Genome Atlas and international consortia have mapped mutation spectra and clinical associations.
Small-molecule tyrosine kinase inhibitors and monoclonal antibodies targeting receptor signaling have been developed and tested in clinical trials led by centers such as GlaxoSmithKline, Pfizer, Novartis, AstraZeneca, and academic groups at Dana-Farber Cancer Institute. Agents include multi-kinase inhibitors and selective compounds that disrupt ATP binding or receptor dimerization; drug resistance mechanisms and combination strategies were explored in translational studies at University of California, Los Angeles and University of Texas Southwestern Medical Center. Translational successes include approved therapies for tumors driven by receptor alterations and ongoing trials for fibrotic diseases coordinated by consortia like European Organisation for Research and Treatment of Cancer and National Cancer Institute.
Category:Receptor tyrosine kinases